Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects

ClinicalTrials.gov ID: NCT01856426

Public ClinicalTrials.gov record NCT01856426. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 8, 2026, 4:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Double-Blind, Randomized, Placebo-controlled, Multi-center Trial to Determine the Safety and Antiviral Effect of Single Doses of EDP239 in Hepatitis C Virus (HCV) Infected Subjects

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is, to assess whether EDP239 can reduce the HCV viral load in HCV gentotype-1 in chronically infected subjects and to further evaluate the safety profile of EDP239.

Study identification

NCT ID: NCT01856426
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Enrollment: 28 participants

Conditions and interventions

Conditions

Hepatitis C

Interventions

EDP239 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 60 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 2013 (Type not available)
Primary completion: Nov 2014 (Actual)
Completion: Oct 2015 (Actual)
Last update posted: Jan 29, 2016

2013 – 2015

United States locations

U.S. sites: 3
U.S. states: 3
U.S. cities: 3

Facility	City	State	ZIP	Site status
Investigative Site	Miami	Florida	33169	—
Investigative Site	San Antonio	Texas	78215	—
Investigative Site	Murray	Utah	84123	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01856426, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 29, 2016 · Synced Oct 8, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01856426 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →